Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash-to-Debt 0.03
NYSE:BSX's Cash-to-Debt is ranked lower than
98% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. NYSE:BSX: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:BSX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.15 Max: 4.69
Current: 0.03
0.03
4.69
Equity-to-Asset 0.40
NYSE:BSX's Equity-to-Asset is ranked lower than
86% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NYSE:BSX: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:BSX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.51 Max: 0.83
Current: 0.4
0.18
0.83
Debt-to-Equity 0.84
NYSE:BSX's Debt-to-Equity is ranked lower than
84% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 0.30 vs. NYSE:BSX: 0.84 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:BSX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06  Med: 0.54 Max: 3.64
Current: 0.84
0.06
3.64
Debt-to-EBITDA 3.24
NYSE:BSX's Debt-to-EBITDA is ranked lower than
67% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. NYSE:BSX: 3.24 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:BSX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -88.33  Med: 3.64 Max: 37.25
Current: 3.24
-88.33
37.25
Interest Coverage 7.13
NYSE:BSX's Interest Coverage is ranked lower than
82% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 66.37 vs. NYSE:BSX: 7.13 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:BSX' s Interest Coverage Range Over the Past 10 Years
Min: 2.47  Med: 3.51 Max: 7.13
Current: 7.13
2.47
7.13
Piotroski F-Score: 7
Altman Z-Score: 2.53
Beneish M-Score: -2.44
WACC vs ROIC
8.22%
5.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating Margin % 17.42
NYSE:BSX's Operating Margin % is ranked higher than
78% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. NYSE:BSX: 17.42 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:BSX' s Operating Margin % Range Over the Past 10 Years
Min: 12.22  Med: 13.1 Max: 17.42
Current: 17.42
12.22
17.42
Net Margin % 5.48
NYSE:BSX's Net Margin % is ranked higher than
50% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. NYSE:BSX: 5.48 )
Ranked among companies with meaningful Net Margin % only.
NYSE:BSX' s Net Margin % Range Over the Past 10 Years
Min: -56.12  Med: -2.45 Max: 5.79
Current: 5.48
-56.12
5.79
ROE % 7.12
NYSE:BSX's ROE % is ranked higher than
51% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. NYSE:BSX: 7.12 )
Ranked among companies with meaningful ROE % only.
NYSE:BSX' s ROE % Range Over the Past 10 Years
Min: -44.65  Med: -2.79 Max: 7.12
Current: 7.12
-44.65
7.12
ROA % 2.75
NYSE:BSX's ROA % is ranked higher than
52% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -0.26 vs. NYSE:BSX: 2.75 )
Ranked among companies with meaningful ROA % only.
NYSE:BSX' s ROA % Range Over the Past 10 Years
Min: -21.16  Med: -1.04 Max: 2.75
Current: 2.75
-21.16
2.75
ROC (Joel Greenblatt) % 79.06
NYSE:BSX's ROC (Joel Greenblatt) % is ranked higher than
90% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 3.87 vs. NYSE:BSX: 79.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:BSX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -144.7  Med: -14.88 Max: 79.06
Current: 79.06
-144.7
79.06
3-Year Revenue Growth Rate 5.20
NYSE:BSX's 3-Year Revenue Growth Rate is ranked higher than
52% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. NYSE:BSX: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:BSX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.5  Med: 4.9 Max: 29
Current: 5.2
-10.5
29
3-Year EBITDA Growth Rate 64.10
NYSE:BSX's 3-Year EBITDA Growth Rate is ranked higher than
95% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. NYSE:BSX: 64.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:BSX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 13.15 Max: 83.1
Current: 64.1
0
83.1
GuruFocus has detected 3 Warning Signs with Boston Scientific Corp NYSE:BSX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:BSX's 30-Y Financials

Financials (Next Earnings Date: 2018-10-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income
» NYSE:BSX's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades
Q3 2017

BSX Guru Trades in Q3 2017

David Tepper 3,752,866 sh (+65.70%)
Joel Greenblatt 28,643 sh (+16.45%)
Julian Robertson 1,069,500 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 936,126 sh (unchged)
Diamond Hill Capital 3,009,893 sh (-0.12%)
PRIMECAP Management 42,168,267 sh (-0.47%)
Vanguard Health Care Fund 39,692,793 sh (-3.47%)
Michael Price 284,200 sh (-3.66%)
Mario Gabelli 527,859 sh (-4.21%)
Pioneer Investments 1,864,993 sh (-5.56%)
Dodge & Cox 302,355 sh (-6.75%)
Jim Simons 2,012,405 sh (-62.07%)
Steven Cohen 125,500 sh (-88.02%)
» More
Q4 2017

BSX Guru Trades in Q4 2017

John Hussman 50,000 sh (New)
David Carlson 750,000 sh (New)
Ray Dalio 176,079 sh (New)
Caxton Associates 44,975 sh (New)
Paul Tudor Jones 195,667 sh (New)
Joel Greenblatt 503,669 sh (+1658.44%)
David Tepper 4,782,683 sh (+27.44%)
PRIMECAP Management 43,877,562 sh (+4.05%)
Vanguard Health Care Fund 40,024,604 sh (+0.84%)
Diamond Hill Capital 3,024,204 sh (+0.48%)
Michael Price 284,200 sh (unchged)
Julian Robertson Sold Out
Steven Cohen Sold Out
Mario Gabelli 452,909 sh (-14.20%)
Dodge & Cox 253,355 sh (-16.21%)
Jim Simons 1,146,305 sh (-43.04%)
Pioneer Investments 854,578 sh (-54.18%)
Eaton Vance Worldwide Health Sciences Fund 816,790 sh (-12.75%)
» More
Q1 2018

BSX Guru Trades in Q1 2018

Jana Partners 4,724,275 sh (New)
Lee Ainslie 71,740 sh (New)
Steven Cohen 1,098,500 sh (New)
David Carlson 870,000 sh (+16.00%)
PRIMECAP Management 44,720,041 sh (+1.92%)
Eaton Vance Worldwide Health Sciences Fund 816,790 sh (unchged)
John Hussman Sold Out
Caxton Associates Sold Out
Joel Greenblatt Sold Out
Diamond Hill Capital 2,999,394 sh (-0.82%)
Pioneer Investments 842,727 sh (-1.39%)
Michael Price 277,500 sh (-2.36%)
Vanguard Health Care Fund 38,541,504 sh (-3.71%)
Jim Simons 1,094,305 sh (-4.54%)
Dodge & Cox 238,355 sh (-5.92%)
David Tepper 3,910,738 sh (-18.23%)
Mario Gabelli 331,409 sh (-26.83%)
Ray Dalio 100,850 sh (-42.72%)
Paul Tudor Jones 26,687 sh (-86.36%)
» More
Q2 2018

BSX Guru Trades in Q2 2018

Leucadia National 25,000 sh (New)
Joel Greenblatt 59,660 sh (New)
Pioneer Investments 2,631,078 sh (+212.21%)
Steven Cohen 1,469,300 sh (+33.76%)
Paul Tudor Jones 30,623 sh (+14.75%)
PRIMECAP Management 44,807,141 sh (+0.19%)
David Carlson 870,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 816,790 sh (unchged)
Ray Dalio Sold Out
Lee Ainslie Sold Out
Jim Simons Sold Out
Diamond Hill Capital 2,912,581 sh (-2.89%)
Mario Gabelli 312,064 sh (-5.84%)
Vanguard Health Care Fund 35,049,014 sh (-9.06%)
Dodge & Cox 211,955 sh (-11.08%)
Jana Partners 3,137,513 sh (-33.59%)
David Tepper 2,528,138 sh (-35.35%)
Michael Price 102,500 sh (-63.06%)
» More
» Details

Insider Trades

Financial Reports

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-06-30 Reduce -9.06%0.21%$26.84 - $34.32 $ 34.4114%35,049,014
David Tepper 2018-06-30 Reduce -35.35%0.39%$26.84 - $34.32 $ 34.4114%2,528,138
Mario Gabelli 2018-06-30 Reduce -5.84%$26.84 - $34.32 $ 34.4114%312,064
Dodge & Cox 2018-06-30 Reduce -11.08%$26.84 - $34.32 $ 34.4114%211,955
Michael Price 2018-06-30 Reduce -63.06%0.57%$26.84 - $34.32 $ 34.4114%102,500
Joel Greenblatt 2018-06-30 New Buy0.03%$26.84 - $34.32 $ 34.4114%59,660
Leucadia National 2018-06-30 New Buy0.06%$26.84 - $34.32 $ 34.4114%25,000
Vanguard Health Care Fund 2018-03-31 Reduce -3.71%0.08%$24.79 - $28.54 $ 34.4127%38,541,504
David Tepper 2018-03-31 Reduce -18.23%0.2%$24.79 - $28.54 $ 34.4127%3,910,738
Mario Gabelli 2018-03-31 Reduce -26.83%0.02%$24.79 - $28.54 $ 34.4127%331,409
Michael Price 2018-03-31 Reduce -2.36%0.02%$24.79 - $28.54 $ 34.4127%277,500
Dodge & Cox 2018-03-31 Reduce -5.92%$24.79 - $28.54 $ 34.4127%238,355
Joel Greenblatt 2018-03-31 Sold Out 0.18%$24.79 - $28.54 $ 34.4127%0
Vanguard Health Care Fund 2017-12-31 Add 0.84%0.02%$24.79 - $29.8 $ 34.4125%40,024,604
David Tepper 2017-12-31 Add 27.44%0.24%$24.79 - $29.8 $ 34.4125%4,782,683
Joel Greenblatt 2017-12-31 Add 1658.44%0.17%$24.79 - $29.8 $ 34.4125%503,669
Mario Gabelli 2017-12-31 Reduce -14.20%0.01%$24.79 - $29.8 $ 34.4125%452,909
Dodge & Cox 2017-12-31 Reduce -16.21%$24.79 - $29.8 $ 34.4125%253,355
Julian Robertson 2017-12-31 Sold Out 5.64%$24.79 - $29.8 $ 34.4125%0
Vanguard Health Care Fund 2017-09-30 Reduce -3.47%0.08%$26.26 - $29.17 $ 34.4125%39,692,793
David Tepper 2017-09-30 Add 65.70%0.61%$26.26 - $29.17 $ 34.4125%3,752,866
Mario Gabelli 2017-09-30 Reduce -4.21%$26.26 - $29.17 $ 34.4125%527,859
Dodge & Cox 2017-09-30 Reduce -6.75%$26.26 - $29.17 $ 34.4125%302,355
Michael Price 2017-09-30 Reduce -3.66%0.04%$26.26 - $29.17 $ 34.4125%284,200
Joel Greenblatt 2017-09-30 Add 16.45%$26.26 - $29.17 $ 34.4125%28,643
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:ISRG, NYSE:EW, NYSE:ZBH, NAS:ALGN, LSE:SN., NYSE:SYK, NAS:ABMD, NYSE:TFX, XSWX:SOON, NYSE:VAR, SZSE:300003, OCSE:WDH, XPAR:DIM, ASX:COH, LSE:CTEC, NZSE:FPH, NYSE:GMED, OCSE:AMBU B, NAS:IART, OCSE:GN » details
Traded in other countries:BSX.Germany,
Headquarter Location:USA
Boston Scientific Corp is a developer, manufacturer, and marketer of medical devices. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract tests, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Top Ranked Articles about Boston Scientific Corp

Boston Scientific Announces Agreement to Acquire VENITI, Inc.
August 8, 2018
Read more...
Boston Scientific Closes Acquisition of Claret Medical, Inc., Announces Positive Reimbursement Decision
August 2, 2018
Read more...
Boston Scientific to Participate in 38th Annual Canaccord Genuity Growth Conference
July 30, 2018
Read more...
The Reasons Behind The Story – Key Research Reports on Facebook, Salesforce, Cherry Hill Mortgage Investment, Boston Scientific, First Merchants, and The Western Union
July 27, 2018
Read more...
Boston Scientific Corporation Recommends Stockholders Reject 'Mini-Tender' Offer by TRC Capital Corporation
July 24, 2018
Read more...
Boston Scientific Announces Agreement to Acquire Claret Medical, Inc.
July 20, 2018
Read more...
Boston Scientific to Acquire Cryterion Medical, Inc.
July 5, 2018
Read more...
Boston Scientific Announces Conference Call Discussing Second Quarter 2018 Financial Results
July 2, 2018
Read more...
Boston Scientific Announces Scheduled Presentations At Digestive Disease Week 2018
June 1, 2018
Read more...
Boston Scientific Announces Schedule of Presentations at EuroPCR 2018
May 16, 2018
Read more...

Ratios

vs
industry		 vs
history
PE Ratio 95.58
BSX's PE Ratio is ranked lower than
98% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. BSX: 95.58 )
Ranked among companies with meaningful PE Ratio only.
BSX' s PE Ratio Range Over the Past 10 Years
Min: 13.87  Med: 48.31 Max: 435
Current: 95.58
13.87
435
Forward PE Ratio 24.57
BSX's Forward PE Ratio is ranked higher than
71% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. BSX: 24.57 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 95.58
BSX's PE Ratio without NRI is ranked lower than
98% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. BSX: 95.58 )
Ranked among companies with meaningful PE Ratio without NRI only.
BSX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.87  Med: 48.31 Max: 435
Current: 95.58
13.87
435
Price-to-Owner-Earnings 57.54
BSX's Price-to-Owner-Earnings is ranked lower than
83% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 32.03 vs. BSX: 57.54 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BSX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.58  Med: 50.42 Max: 985.26
Current: 57.54
11.58
985.26
PB Ratio 6.13
BSX's PB Ratio is ranked lower than
70% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. BSX: 6.13 )
Ranked among companies with meaningful PB Ratio only.
BSX' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.59 Max: 6.13
Current: 6.13
0.59
6.13
PS Ratio 5.06
BSX's PS Ratio is ranked lower than
59% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. BSX: 5.06 )
Ranked among companies with meaningful PS Ratio only.
BSX' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 2.23 Max: 5.06
Current: 5.06
1.02
5.06
Price-to-Free-Cash-Flow 73.53
BSX's Price-to-Free-Cash-Flow is ranked lower than
61% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.44 vs. BSX: 73.53 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BSX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.21  Med: 22.81 Max: 220
Current: 73.53
7.21
220
Price-to-Operating-Cash-Flow 51.82
BSX's Price-to-Operating-Cash-Flow is ranked lower than
66% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 20.01 vs. BSX: 51.82 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BSX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 16.74 Max: 62.72
Current: 51.82
5.75
62.72
EV-to-EBIT 37.46
BSX's EV-to-EBIT is ranked lower than
73% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.76 vs. BSX: 37.46 )
Ranked among companies with meaningful EV-to-EBIT only.
BSX' s EV-to-EBIT Range Over the Past 10 Years
Min: -5167.6  Med: -3.1 Max: 317.6
Current: 37.46
-5167.6
317.6
EV-to-EBITDA 26.86
BSX's EV-to-EBITDA is ranked lower than
69% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 18.14 vs. BSX: 26.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.1  Med: 11.4 Max: 242.5
Current: 26.86
-680.1
242.5
EV-to-Revenue 5.67
BSX's EV-to-Revenue is ranked lower than
62% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 3.73 vs. BSX: 5.67 )
Ranked among companies with meaningful EV-to-Revenue only.
BSX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1  Med: 2.85 Max: 5.7
Current: 5.67
1
5.7
Current Ratio 0.83
BSX's Current Ratio is ranked lower than
94% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. BSX: 0.83 )
Ranked among companies with meaningful Current Ratio only.
BSX' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.55 Max: 7.77
Current: 0.83
0.52
7.77
Quick Ratio 0.60
BSX's Quick Ratio is ranked lower than
93% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. BSX: 0.60 )
Ranked among companies with meaningful Quick Ratio only.
BSX' s Quick Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.18 Max: 6.29
Current: 0.6
0.33
6.29
Days Inventory 140.66
BSX's Days Inventory is ranked higher than
50% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 143.61 vs. BSX: 140.66 )
Ranked among companies with meaningful Days Inventory only.
BSX' s Days Inventory Range Over the Past 10 Years
Min: 116.64  Med: 135.91 Max: 159.64
Current: 140.66
116.64
159.64
Days Sales Outstanding 60.98
BSX's Days Sales Outstanding is ranked higher than
58% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 69.21 vs. BSX: 60.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.51  Med: 61.98 Max: 66.79
Current: 60.98
58.51
66.79
Days Payable 52.70
BSX's Days Payable is ranked higher than
60% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. BSX: 52.70 )
Ranked among companies with meaningful Days Payable only.
BSX' s Days Payable Range Over the Past 10 Years
Min: 24.12  Med: 34.67 Max: 72.7
Current: 52.7
24.12
72.7

Buy Back

vs
industry		 vs
history
3-Year Average Share Buyback Ratio -1.10
BSX's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. BSX: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.9  Med: -1 Max: 4.6
Current: -1.1
-25.9
4.6

Valuation & Return

vs
industry		 vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.60
BSX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
64% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. BSX: 3.60 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BSX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.51  Med: 1.62 Max: 500
Current: 3.6
0.51
500
Price-to-Median-PS-Value 2.27
BSX's Price-to-Median-PS-Value is ranked lower than
86% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. BSX: 2.27 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BSX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.49 Max: 4.28
Current: 2.27
0.48
4.28
Earnings Yield (Greenblatt) % 2.67
BSX's Earnings Yield (Greenblatt) % is ranked higher than
62% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.74 vs. BSX: 2.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BSX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -34.3  Med: -0.25 Max: 9.1
Current: 2.67
-34.3
9.1
Forward Rate of Return (Yacktman) % -15.64
BSX's Forward Rate of Return (Yacktman) % is ranked higher than
96% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. BSX: -15.64 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BSX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.64  Med: 6.3 Max: 15.4
Current: -15.64
-15.64
15.4

More Statistics

Revenue (TTM) (Mil) $9,499.00
EPS (TTM) $ 0.36
Beta0.97
Volatility20.27%
52-Week Range $24.54 - 37.30
Shares Outstanding (Mil)1,382.92

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 9,841 10,555 11,296
EBIT (Mil $) 1,767 2,180
EBITDA (Mil $) 2,641 3,072
EPS ($) 1.13 1.29 1.33
EPS without NRI ($) 1.13 1.29 1.33
EPS Growth Rate
(Future 3Y To 5Y Estimate)		 40.61%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

» More Articles for NYSE:BSX

Headlines

Articles On GuruFocus.com
Boston Scientific Announces Agreement to Acquire VENITI, Inc. Aug 08 2018 
Boston Scientific Closes Acquisition of Claret Medical, Inc., Announces Positive Reimbursement Decis Aug 02 2018 
Boston Scientific to Participate in 38th Annual Canaccord Genuity Growth Conference Jul 30 2018 
The Reasons Behind The Story – Key Research Reports on Facebook, Salesforce, Cherry Hill Mortgage Jul 27 2018 
Boston Scientific Corporation Recommends Stockholders Reject 'Mini-Tender' Offer by TRC Capital Corp Jul 24 2018 
Boston Scientific Announces Agreement to Acquire Claret Medical, Inc. Jul 20 2018 
Boston Scientific to Acquire Cryterion Medical, Inc. Jul 05 2018 
Boston Scientific Announces Conference Call Discussing Second Quarter 2018 Financial Results Jul 02 2018 
Boston Scientific Announces Scheduled Presentations At Digestive Disease Week 2018 Jun 01 2018 
Boston Scientific Announces Schedule of Presentations at EuroPCR 2018 May 16 2018 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}